NASDAQ$DXCM
DexCom Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Dexcom reported strong financial results driven by volume growth and new customer additions, while also advancing key strategic initiatives such as receiving FDA clearance for Stelo and launching Dexcom ONE+ in Europe.
Dexcom reported a strong start to 2024 with revenue growth of 24% year-over-year to $921.0 million. The company also received FDA clearance for Stelo and launched Dexcom ONE+ in eight European countries.
- Revenue grew 24% year-over-year to $921.0 million.
- U.S. and International revenue both grew 24% year-over-year.
- GAAP operating income was $101.1 million, or 11.0% of revenue.
- FDA clearance was received for Stelo, a new CGM system designed for people with type 2 diabetes not on insulin therapy.
Headline financials
Revenue & EPS history
DexCom · Revenue · Quarterly
$921M
Forward guidance
Dexcom is updating fiscal year 2024 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:
Tailwinds
- Revenue of approximately $4.20 - 4.35 billion (17 - 21% organic growth)
- Non-GAAP Gross Profit Margin of approximately 63 - 64%
- Non-GAAP Operating Margin of approximately 20%
- Adjusted EBITDA Margin of approximately 29%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.6%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.8%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+31.1%
Q2 2018
Best reaction
-42.8%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.8% | +1.4% | +23.8% | |
| Q4 2025 | +7.6% | +11.9% | -1.3% | |
| Q3 2025 | +1.6% | -13.1% | -6.9% | |
| Q1 2025 | +16.0% | +18.6% | +22.1% | |
| Q4 2024 | +5.9% | +6.6% | -15.9% | |
| Q3 2024 | +1.3% | -0.3% | +0.5% | |
| Q2 2024 | -42.8% | -37.7% | -33.8% | |
| Q1 2024 | -9.8% | -7.6% | -7.6% | |
| Q4 2023 | -4.8% | -7.6% | +6.8% | |
| Q3 2023 | +5.9% | +5.3% | +33.9% | |
| Q2 2023 | +1.3% | -6.6% | -22.9% | |
| Q1 2023 | -2.9% | -5.5% | -7.9% | |
| Q4 2022 | +7.3% | +7.9% | -1.9% | |
| Q3 2022 | +17.8% | +16.0% | +9.2% | |
| Q2 2022 | -4.3% | +2.9% | -1.5% | |
| Q1 2022 | -1.1% | -4.3% | -30.0% | |
| Q4 2021 | -6.1% | -6.8% | -12.9% | |
| Q3 2021 | +11.6% | +14.5% | +6.0% | |
| Q2 2021 | +12.1% | +13.3% | +13.2% | |
| Q1 2021 | -9.3% | -12.8% | -13.2% | |
| Q4 2020 | +3.3% | +1.2% | -10.4% | |
| Q3 2020 | -16.5% | -23.5% | -25.2% | |
| Q2 2020 | +0.9% | +2.9% | +1.0% | |
| Q1 2020 | +3.1% | +1.9% | +8.0% | |
| Q4 2019 | +15.4% | +20.3% | -0.8% | |
| Q3 2019 | +26.8% | +33.9% | +46.4% | |
| Q2 2019 | -5.2% | -9.1% | +9.7% | |
| Q1 2019 | -0.6% | +0.9% | +0.2% | |
| Q4 2018 | -5.9% | -4.1% | -11.3% | |
| Q3 2018 | +10.5% | +14.2% | -1.0% | |
| Q2 2018 | +31.1% | +28.1% | +51.8% | |
| Q1 2018 | +14.2% | +16.6% | +25.6% | |
| Q4 2017 | -1.4% | +6.6% | +3.0% | |
| Q3 2017 | +6.1% | +11.1% | +29.0% | |
| Q2 2017 | +7.1% | +6.8% | +12.0% | |
| Q1 2017 | -7.1% | -4.3% | -16.0% | |
| Q4 2016 | +2.9% | +1.6% | +7.3% | |
| Q3 2016 | -19.6% | -20.9% | -19.0% | |
| Q2 2016 | -1.9% | -1.5% | -1.0% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | +1.4% | — | — | |
| Q3 2015 | -3.0% | — | — | |
| Q2 2015 | +9.9% | — | — | |
| Q1 2015 | -0.7% | — | — | |
| Q4 2014 | +0.6% | — | — | |
| Q3 2014 | +15.7% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | -3.1% | — | — | |
| Q3 2013 | +16.4% | — | — | |
| Q2 2013 | +18.7% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | +9.2% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | -16.2% | — | — | |
| Q2 2011 | -17.7% | — | — | |
| Q1 2011 | -1.7% | — | — | |
| Q4 2010 | +5.3% | — | — | |
| Q3 2010 | -22.1% | — | — | |
| Q2 2010 | +5.5% | — | — | |
| Q1 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro